PY2240956A - Nuevos Compuestos bicíclicos y sus usos - Google Patents

Nuevos Compuestos bicíclicos y sus usos

Info

Publication number
PY2240956A
PY2240956A PY202202240956A PY2240956A PY2240956A PY 2240956 A PY2240956 A PY 2240956A PY 202202240956 A PY202202240956 A PY 202202240956A PY 2240956 A PY2240956 A PY 2240956A PY 2240956 A PY2240956 A PY 2240956A
Authority
PY
Paraguay
Prior art keywords
sub
compounds
bicyclic compounds
new bicyclic
new
Prior art date
Application number
PY202202240956A
Other languages
English (en)
Inventor
Decker Andrea
LIMAM Fatma
Zecri Fréderic
Gogniat Geoffrey
Möbitz Henrik
YU Huangchao
Hamon Jacques
SOTO Jessica
Schoepfer Joseph
Hans-Hermann HINRICHS Jürgen
BRUN Jvan
Furegati Markus
Schmiedeberg Niko
Holzer Philipp
Strang Ross
NOCITO Sandro
Yao Shuping
PLATTNER Simone
Zhang Sisi
Bordas Vincent
Gong Wanben
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PY2240956A publication Critical patent/PY2240956A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un compuesto, o una sal farmacéuticamente aceptable del mismo, de la fórmula (I): en donde R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>26</sub>, R<sub>27</sub>, y, R, M, W, L, V, T, Y, J, K y A han sido descriptos en la presente, usos terapéuticos de dichos compuestos, usos de dichos compuestos como químicos de investigación, una composición farmacéutica y combinaciones que comprenden dichos compuestos, y métodos para elaborar los compuestos de la invención.
PY202202240956A 2021-05-26 2022-05-24 Nuevos Compuestos bicíclicos y sus usos PY2240956A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021096104 2021-05-26
CN2022085537 2022-04-07

Publications (1)

Publication Number Publication Date
PY2240956A true PY2240956A (es) 2023-11-09

Family

ID=82019774

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202202240956A PY2240956A (es) 2021-05-26 2022-05-24 Nuevos Compuestos bicíclicos y sus usos

Country Status (24)

Country Link
US (2) US11878973B2 (es)
EP (1) EP4347596A1 (es)
JP (2) JP7753397B2 (es)
KR (1) KR20240013168A (es)
CN (1) CN117425657A (es)
AR (1) AR125966A1 (es)
AU (1) AU2022279728A1 (es)
BR (1) BR112023024551A2 (es)
CA (1) CA3219799A1 (es)
CL (1) CL2023003489A1 (es)
CO (1) CO2023018119A2 (es)
CR (1) CR20230616A (es)
DO (1) DOP2023000256A (es)
EC (1) ECSP23095674A (es)
IL (1) IL308229A (es)
JO (1) JOP20230304A1 (es)
MX (1) MX2023013892A (es)
PE (1) PE20240587A1 (es)
PH (1) PH12023553140A1 (es)
PY (1) PY2240956A (es)
TW (1) TW202313616A (es)
UY (1) UY39786A (es)
WO (1) WO2022249060A1 (es)
ZA (1) ZA202310237B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3806850A2 (en) * 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells
UY40470A (es) * 2022-10-12 2024-05-15 Novartis Ag Compuestos tricíclicos y sus usos
EP4619104A1 (en) * 2022-11-16 2025-09-24 Novartis AG Bicyclic heterocycles and their use as wrn inhibitors
US20240197715A1 (en) 2022-11-18 2024-06-20 Novartis Ag Pharmaceutical combinations and uses thereof
CN120225526A (zh) 2022-11-23 2025-06-27 诺华股份有限公司 用于治疗癌症的稠合吡啶的固体形式
WO2024120378A2 (en) * 2022-12-05 2024-06-13 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Triazole compounds, preparation methods and medicinal uses thereof
WO2024140597A1 (zh) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Wrn解旋酶抑制剂
EP4644393A1 (en) 2022-12-30 2025-11-05 Suzhou Puhe Biopharma Co., Ltd. Wrn inhibitor
WO2024153155A1 (zh) * 2023-01-18 2024-07-25 成都微芯药业有限公司 双杂环wrn抑制剂、其制备方法及其应用
WO2024153244A1 (zh) * 2023-01-20 2024-07-25 南京再明医药有限公司 含氮类化合物
WO2024155884A1 (en) * 2023-01-20 2024-07-25 Synnovation Therapeutics, Inc. Heterocyclic compounds as wrn inhibitors
WO2024187049A1 (en) * 2023-03-08 2024-09-12 Synnovation Therapeutics, Inc. Heterocyclic compounds as wrn inhibitors
WO2024193716A1 (zh) * 2023-03-17 2024-09-26 南京再明医药有限公司 三唑并嘧啶类化合物
TW202444720A (zh) * 2023-03-23 2024-11-16 大陸商北京丹擎醫藥科技有限公司 雙環衍生物，及其組合物和應用
CN118684688A (zh) * 2023-03-24 2024-09-24 上海济煜医药科技有限公司 一类作为wrn解旋酶抑制剂的杂环类化合物及其制备方法和应用
EP4692088A1 (en) 2023-03-24 2026-02-11 Shanghai Jeyou Pharmaceutical Co., Ltd. Compound acting as wrn helicase inhibitor
EP4698534A1 (en) * 2023-04-21 2026-02-25 Nimbus Wadjet, Inc. [1,2,4]triazolo[1,5-a]pyrimidinone wrn inhibitors
WO2024222677A1 (zh) * 2023-04-25 2024-10-31 苏州浦合医药科技有限公司 Wrn抑制剂
CN116496223A (zh) * 2023-04-26 2023-07-28 福建凯昕药业有限公司 5-溴-4-甲基-2-三氟甲基嘧啶的一种制备方法
WO2024230828A1 (en) * 2023-05-11 2024-11-14 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
AU2024274507A1 (en) * 2023-05-17 2025-12-18 Insilico Medicine Ip Limited Spiro derivatives as wrn inhibitors
TW202510857A (zh) * 2023-06-01 2025-03-16 英商葛蘭素史密斯克藍智慧財產權有限公司 化合物及其用途
UY40772A (es) 2023-06-08 2024-12-31 Nimbus Wadjet Inc Inhibidores de wrn
EP4724446A1 (en) * 2023-06-09 2026-04-15 Nimbus Wadjet, Inc. Oxazolopyridin-7(4h)-one wrn inhibitors
CN121358739A (zh) * 2023-06-12 2026-01-16 抟相医药(上海)有限公司 新型化合物，包含其的组合物及其用途
CN121419979A (zh) * 2023-06-13 2026-01-27 林伯士瓦吉特公司 噻唑并吡啶-7(4h)-酮wrn抑制剂
WO2024255790A1 (zh) * 2023-06-15 2024-12-19 勤浩医药（苏州）有限公司 稠环化合物、包含其的药物组合物及其用途
TW202506111A (zh) * 2023-07-07 2025-02-16 美商林伯士瓦吉特公司 三唑并wrn抑制劑
WO2025014846A1 (en) * 2023-07-11 2025-01-16 Merck Sharp & Dohme Llc Spirocyclic wrn helicase inhibitors
WO2025021148A1 (zh) * 2023-07-27 2025-01-30 贝达药业股份有限公司 Wrn抑制剂及其药物组合物和应用
CN121666389A (zh) * 2023-08-01 2026-03-13 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025040168A1 (en) * 2023-08-24 2025-02-27 Zai Lab (Shanghai) Co., Ltd. Spiro-triazolopyrimidine analogues as wrn inhibitors and uses thereof
CN119528909A (zh) * 2023-08-29 2025-02-28 上海科恩泰生物医药科技有限公司 一种抑制wrn解旋酶的双杂环衍生物、含其的药物组合物及其应用
AU2024332123A1 (en) * 2023-08-29 2026-02-26 Eikon Therapeutics, Inc. Compositions comprising werner syndrome helicase inhibitors and methods of using the same
TW202515558A (zh) * 2023-09-08 2025-04-16 美商Ｍｏｍａ治療公司 三環衍生物及相關用途
WO2025067429A1 (en) * 2023-09-28 2025-04-03 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
CN121646596A (zh) * 2023-10-12 2026-03-10 楚浦创制（武汉）医药科技有限公司 吡啶酮并环类衍生物及其应用
WO2025087274A1 (zh) * 2023-10-27 2025-05-01 浙江海正药业股份有限公司 氮杂双环类衍生物及其制备方法和用途
WO2025106693A1 (en) * 2023-11-16 2025-05-22 Eikon Therapeutics, Inc. Methods and compositions for treating cancers with high microsatellite instability levels
WO2025106949A1 (en) * 2023-11-16 2025-05-22 Radd Pharmaceuticals, Inc. Wrn inhibitors
CN117865963B (zh) * 2023-12-15 2026-02-24 上海凌凯科技股份有限公司 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物
WO2025130971A1 (zh) * 2023-12-21 2025-06-26 勤浩医药（苏州）有限公司 稠环化合物、包含其的药物组合物及其用途
US20250206738A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors
WO2025137640A1 (en) * 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds
TW202542158A (zh) * 2023-12-29 2025-11-01 大陸商勤浩醫藥(蘇州)有限公司 稠環化合物、包含其的藥物組合物及其用途
WO2025152932A1 (zh) * 2024-01-15 2025-07-24 上海齐鲁制药研究中心有限公司 一种三唑并嘧啶类衍生物、其制备方法和应用
WO2025152750A1 (zh) * 2024-01-17 2025-07-24 成都微芯药业有限公司 双杂环wrn抑制剂、其制备方法及其应用
CN120398919B (zh) * 2024-02-01 2026-04-07 福石生物科技(合肥)有限公司 作为wrn抑制剂的螺环衍生物及其应用
CN120424093A (zh) * 2024-02-02 2025-08-05 中国科学院上海药物研究所 螺环类化合物、包含其的药物组合物及其用途
WO2025162478A1 (en) * 2024-02-04 2025-08-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025172934A1 (en) 2024-02-16 2025-08-21 Janssen Pharmaceutica Nv Triazolo[4,5-b]pyridine compounds useful as inhibitors of werner syndrome recq helicase (wrn)
WO2025180452A1 (zh) * 2024-02-29 2025-09-04 南京再明医药有限公司 Wrn抑制剂化合物及其应用
WO2025191176A1 (en) 2024-03-14 2025-09-18 Forx Therapeutics Ag Wrn inhibitory compounds
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof
WO2025223388A1 (zh) * 2024-04-22 2025-10-30 南京再明医药有限公司 三并环类化合物及其应用
WO2025223396A1 (en) * 2024-04-22 2025-10-30 3H Pharmaceuticals Co., Ltd. Fused tricyclic compounds and methods of use thereof
WO2025232693A1 (en) * 2024-05-08 2025-11-13 Nuphase Therapeutics (Shanghai) Limited., Co. Novel compounds, compositions comprising the same and uses thereof
WO2025237361A1 (zh) * 2024-05-16 2025-11-20 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025250620A1 (en) * 2024-05-28 2025-12-04 Nimbus Wadjet, Inc. Tricyclic fused wrn inhibitors
WO2025252190A1 (en) * 2024-06-07 2025-12-11 Cullgen Inc. Targeted degraders of werner syndrome recq helicase
WO2025261355A1 (en) * 2024-06-20 2025-12-26 Insilico Medicine Ip Limited Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof
WO2025261486A1 (en) * 2024-06-22 2025-12-26 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2026006796A1 (en) * 2024-06-27 2026-01-02 Eikon Therapeutics, Inc. Compositions comprising werner syndrome helicase inhibitors and methods of using the same
WO2026003380A1 (en) 2024-06-28 2026-01-02 Forx Therapeutics Ag Wrn inhibitory compounds
CN121226261A (zh) * 2024-06-28 2025-12-30 武汉人福创新药物研发中心有限公司 作为wrn抑制剂的含芳香环化合物及其应用
WO2026012391A1 (zh) * 2024-07-10 2026-01-15 广州科恩泰生物医药科技有限公司 一种抑制wrn解旋酶的含氮杂环衍生物、含其的药物组合物及其应用
WO2026015855A1 (en) * 2024-07-12 2026-01-15 Nimbus Wadjet, Inc. Spirocyclic wrn inhibitors
WO2026028180A1 (en) 2024-08-01 2026-02-05 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7(4h)-one derivatives useful as inhibitors of wrn
WO2026028179A1 (en) 2024-08-01 2026-02-05 Janssen Pharmaceutica Nv Compounds useful as inhibitors of werner syndrome recq helicase (wrn)
WO2026039591A1 (en) * 2024-08-15 2026-02-19 Synnovation Therapeutics, Inc. Compounds comprising a fused tetracyclic group useful as wrn inhibitors
CN119431379B (zh) * 2024-11-06 2026-04-24 中国药科大学 Wrn降解剂及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CN101528754A (zh) * 2006-08-29 2009-09-09 波士顿大学信托人 使用结合wrn的分子的治疗方法
WO2008057601A2 (en) 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
US20160002247A1 (en) * 2013-03-01 2016-01-07 The University Of Tokyo 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
WO2018229683A1 (en) * 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
MX2020013120A (es) 2018-06-04 2021-07-21 Broad Inst Inc Tratamiento terapéutico de cánceres de microsatélites inestables.
EP3806850A2 (en) * 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
US20210171958A1 (en) 2018-08-23 2021-06-10 Foghorn Therapeutics Inc. Methods of treating cancer
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
US20230348518A1 (en) * 2020-10-05 2023-11-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Helicase inhibitors for treatment of medical disorders

Also Published As

Publication number Publication date
KR20240013168A (ko) 2024-01-30
CA3219799A1 (en) 2022-12-01
US20240360118A1 (en) 2024-10-31
JOP20230304A1 (ar) 2023-11-23
AU2022279728A1 (en) 2023-11-16
TW202313616A (zh) 2023-04-01
UY39786A (es) 2023-01-31
ECSP23095674A (es) 2024-01-31
JP2024522345A (ja) 2024-06-18
CR20230616A (es) 2024-05-06
EP4347596A1 (en) 2024-04-10
US11878973B2 (en) 2024-01-23
CN117425657A (zh) 2024-01-19
PE20240587A1 (es) 2024-03-21
AR125966A1 (es) 2023-08-30
WO2022249060A1 (en) 2022-12-01
DOP2023000256A (es) 2024-01-31
JP7753397B2 (ja) 2025-10-14
ZA202310237B (en) 2025-02-26
JP2026021315A (ja) 2026-02-10
CO2023018119A2 (es) 2023-12-29
PH12023553140A1 (en) 2024-04-29
IL308229A (en) 2024-01-01
MX2023013892A (es) 2023-12-11
BR112023024551A2 (pt) 2024-02-15
US20230046859A1 (en) 2023-02-16
CL2023003489A1 (es) 2024-06-28

Similar Documents

Publication Publication Date Title
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
UY40470A (es) Compuestos tricíclicos y sus usos
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2021003202A1 (es) Compuestos de pirrolidina
MX2021011606A (es) Compuestos dirigidos a prmt5.
AR111820A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue
CR20200382A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CO2021017202A2 (es) Compuestos tricíclicos
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR134040A1 (es) Moduladores de mrgprx2 y métodos de tratamiento relacionados
CO2023012903A2 (es) Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2)
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2023011518A (es) Compuestos heterocíclicos novedosos y sus usos.
CO2025005872A2 (es) Compuestos tricíclicos y sus usos
CR20230458A (es) Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B
AR131249A1 (es) Derivados de heteroarilo bicíclicos útiles como agentes anticancerígenos
AR129367A1 (es) Derivados de pirazol como agonistas de sting
AR114263A1 (es) Compuestos terapéuticos y métodos para utilizarlos